☆ 4.7 Editorial Material

Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases

CLINICAL CANCER RESEARCH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Managing Central Nervous System Spread of Lung Cancer: The State of the Art

David Chun Cheong Tsui et al.

Summary: Considerable progress has been made in the management of brain metastases (BrM) in lung cancer, with advances in radiation and medical oncology. Ongoing trials are exploring new focal therapy options, improving patient selection for whole brain radiotherapy, and evaluating the role of various treatment strategies, including targeted therapy and immunotherapy. Future research will focus on further understanding the central nervous system activity of these therapies and optimizing the integration of multidisciplinary approaches for BrM management.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Joshua K. Sabari et al.

Summary: Patients with KRAS-mutant NSCLC have a high propensity to develop brain metastases. Adagrasib has shown penetration into the cerebrospinal fluid and demonstrated antitumor activity in multiple preclinical models, supporting its potential clinical activity in the brain for patients with KRASG12C-mutant NSCLC and untreated brain metastases.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer

Jarrett J. Failing et al.

Summary: Loss of HLA class 1 expression is a mechanism of tumor immune escape and may contribute to resistance to immunotherapy. Patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors can have discordant responses between brain metastases and extracranial sites of disease. While there is moderate agreement in HLA class 1 expression between primary lung tumor and brain metastasis pairs, HLA expression is incongruent in nearly one quarter of patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

E. Felip et al.

Summary: The study showed that lorlatinib had clinically meaningful intracranial and extracranial antitumor activity in ALK-positive NSCLC patients who had progressed on second-generation ALK TKIs. The efficacy was particularly notable in patients with fewer lines of therapy, with elevated intracranial ORR compared to extracranial ORR.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah et al.

Summary: Selpercatinib demonstrates robust and durable intracranial efficacy in patients with RET fusion-positive NSCLC.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Rudolf M. Huber et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Genetics & Heredity

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

David J. H. Shih et al.

NATURE GENETICS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Contraction of T cell richness in lung cancer brain metastases

Aaron S. Mansfield et al.

SCIENTIFIC REPORTS (2018)

添加到收藏夹

Article Oncology

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Nancy U. Lin et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

A. S. Mansfield et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer

Shirish M. Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases

Paul K. Paik et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Oncology

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.